Antipsychotic Drugs

Clozapine's D2 receptor affinity is relatively modest compared with other antipsychotics, yet it is more effective than any other agent in treatment-resistant schizophrenia. This paradox — high efficacy with low D2 affinity — reflects the breadth and complexity of clozapine's receptor profile. It blocks D2, D4, D1, serotonin 5-HT2A, serotonin 5-HT2C, histamine H1, muscarinic M1, and alpha-1 adrenergic receptors simultaneously. No single receptor interaction accounts for its superior efficacy; the multi-receptor profile as a whole appears to be the active principle. Its low and rapidly dissociating D2 occupancy — approximately 40 to 60 percent at therapeutic doses, well below the 65 to 80 percent range required by other antipsychotics — also means it produces essentially no extrapyramidal symptoms and no elevation of prolactin.

Treatment-resistant schizophrenia is defined as failure of adequate symptom control despite two adequate antipsychotic trials at adequate doses for adequate durations. Approximately 20 to 30 percent of patients with schizophrenia meet this definition. Clozapine produces meaningful clinical response in approximately 30 to 60 percent of treatment-resistant patients — compared with near-zero response rates to further trials of standard antipsychotics in this population. No other antipsychotic, strategy, or combination has been shown to match these response rates.

Clozapine is also the only antipsychotic with a Food and Drug Administration indication specifically for reducing suicidal behavior in schizophrenia and schizoaffective disorder, supported by a large international trial showing reduced suicidality compared with olanzapine. Current guidelines recommend initiating clozapine after the second antipsychotic trial failure — not as a last resort after exhausting every other option. Delays beyond this threshold expose patients to continued psychosis, progressive functional decline, and suicide risk that clozapine could have reduced.

Clozapine causes agranulocytosis — defined as an absolute neutrophil count below 500 cells per microliter — in approximately 0.8 to 1 percent of patients. Agranulocytosis is idiosyncratic, not dose-dependent, and can be fatal if undetected. In the United States, clozapine is available only through the Clozapine Risk Evaluation and Mitigation Strategy program, which requires absolute neutrophil count monitoring before every dispensing: weekly for the first 6 months, every two weeks for months 6 to 12, then monthly thereafter. The drug is dispensed only when the count is confirmed adequate. This mandatory monitoring system means that agranulocytosis, when it develops, is almost always caught before it becomes life-threatening.

Benign ethnic neutropenia — a lower baseline absolute neutrophil count that occurs in individuals of African, Middle Eastern, and Afro-Caribbean ancestry without increased infection risk — is an important consideration. The Risk Evaluation and Mitigation Strategy program now includes adjusted monitoring thresholds for patients with benign ethnic neutropenia to prevent inappropriate clozapine discontinuation in this population.

Clozapine produces the most pronounced weight gain of any antipsychotic, averaging 4 to 5 kilograms in the first year with continued accumulation in susceptible patients. New-onset type 2 diabetes mellitus and diabetic ketoacidosis have been reported even in patients without prior metabolic disease. Sialorrhea — excessive salivation — occurs paradoxically despite clozapine's anticholinergic activity, because it acts as an agonist at muscarinic M4 receptors in the salivary glands. Dose-dependent seizure risk reaches approximately 5 percent at doses above 600 milligrams per day, making clozapine the highest seizure-risk antipsychotic; valproate is the preferred antiseizure drug adjunct when needed, because carbamazepine is contraindicated with clozapine due to additive bone marrow suppression. Orthostatic hypotension from alpha-1 blockade requires slow titration starting at 12.5 milligrams once or twice daily. Myocarditis — a rare but potentially fatal cardiac complication — occurs predominantly in the first 6 to 8 weeks and warrants baseline and early monitoring of troponin and C-reactive protein.

At low doses — 25 to 100 milligrams — quetiapine's clinical effect is dominated by histamine H1 and alpha-1 adrenergic blockade, producing sedation and orthostatic hypotension with minimal antipsychotic activity. Antipsychotic effect requires doses of 400 to 800 milligrams per day in most patients, at which point transient peak D2 occupancy during the first few hours after each dose reaches the therapeutic range. Because D2 occupancy falls rapidly between doses, sustained nigrostriatal blockade — the driver of extrapyramidal symptoms — does not accumulate, and quetiapine at any approved dose produces essentially no extrapyramidal symptoms and no elevation of prolactin.

Quetiapine has one of the broadest approved indication ranges of any antipsychotic. Food and Drug Administration-approved indications include schizophrenia (acute and maintenance), bipolar I disorder mania (acute and maintenance), bipolar depression (as quetiapine extended-release), and as adjunctive therapy in major depressive disorder (as quetiapine extended-release). The approval for bipolar depression — one of the most difficult phases of bipolar disorder to treat — is supported by large randomized trials demonstrating superiority over placebo on depressive rating scales.

Off-label, quetiapine at low doses (25 to 100 milligrams) is widely used as a sleep aid and for anxiety in psychiatric populations, driven by its potent H1-mediated sedation. This off-label use carries the full metabolic and cardiac risks of the drug at any dose — these risks do not disappear at low doses merely because the antipsychotic effect is absent.

Quetiapine's metabolic adverse effects are intermediate — meaningful weight gain (averaging 2 to 3 kilograms at antipsychotic doses) and modest glucose dysregulation, less pronounced than olanzapine or clozapine but more than ziprasidone, lurasidone, or aripiprazole. Orthostatic hypotension from alpha-1 blockade is prominent during initiation and requires gradual dose titration starting at 25 to 50 milligrams twice daily, particularly in elderly patients.

Quetiapine is primarily metabolized by cytochrome P450 3A4, making it sensitive to strong inhibitors and inducers of this enzyme. Strong cytochrome P450 3A4 inhibitors — including azole antifungals and clarithromycin — raise quetiapine levels substantially and require dose reduction to approximately one-sixth of the standard dose during co-administration. Strong cytochrome P450 3A4 inducers — including carbamazepine and rifampin — can reduce quetiapine levels by up to 90 percent, potentially rendering standard doses subtherapeutic.

Both clozapine and olanzapine are primarily metabolized by cytochrome P450 1A2, making them sensitive to the same enzyme inhibitors and inducers. Fluvoxamine — a potent cytochrome P450 1A2 inhibitor used for obsessive-compulsive disorder — raises clozapine plasma levels five to tenfold at standard doses, an interaction so dramatic that it has been deliberately exploited clinically: by adding fluvoxamine, clozapine can be maintained at lower doses that reduce agranulocytosis risk while retaining therapeutic plasma levels, but this requires careful plasma level monitoring and clozapine dose reduction to approximately 25 to 33 percent of the standard dose. Ciprofloxacin raises clozapine levels by approximately 60 percent and requires temporary dose reduction during antibiotic courses. Cigarette smoking induces cytochrome P450 1A2 and reduces both clozapine and olanzapine levels by 40 to 50 percent in heavy smokers — any change in smoking status mandates reassessment of the antipsychotic dose. Carbamazepine induces cytochrome P450 1A2 substantially and is contraindicated with clozapine because it also adds bone marrow suppression risk independently.

Quetiapine's exclusive dependence on cytochrome P450 3A4 creates large-magnitude drug interactions. Strong inhibitors — azole antifungals, clarithromycin, ritonavir — can raise quetiapine levels approximately fivefold and require dose reduction to one-sixth of the standard dose. Strong inducers — carbamazepine, rifampin, phenytoin, St. John's Wort — can reduce quetiapine levels by up to 90 percent, potentially rendering standard antipsychotic doses completely ineffective; if the combination cannot be avoided, quetiapine doses may need to increase fivefold, with a corresponding mandatory dose reduction when the inducer is stopped to avoid toxicity.

Risperidone is converted by cytochrome P450 2D6 to its active metabolite paliperidone. Strong cytochrome P450 2D6 inhibitors — fluoxetine, paroxetine, bupropion — impair this conversion, raising risperidone levels while reducing paliperidone; a dose reduction of approximately 50 percent should be considered when adding a strong inhibitor to established risperidone therapy. Because the combined receptor occupancy of risperidone plus paliperidone determines the clinical effect, cytochrome P450 2D6 phenotype (poor versus extensive metabolizer) also affects dose-response but less dramatically than for agents dependent on a single compound. Paliperidone itself bypasses cytochrome P450 2D6 entirely through renal clearance and is therefore unaffected by cytochrome P450 2D6 inhibitors.